Fate Therapeutics Inc (FATE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.53 (+0.40%), Market cap $0.20B, 52-week low–high $0.92 ~ $2.43.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-der
Financial statements, price targets, institutional (13F) holdings and related news for Fate Therapeutics Inc are updated in real time on BlackAll Trade.
Fate Therapeutics Inc trades at $2.53 (+0.40%). Real-time quotes and charts are available on BlackAll Trade.
Fate Therapeutics Inc has a market cap of about $0.20B.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company'